Obstetrics & Gynecology Doctors in Furlong, PA Accepting Medicare

2 Obstetrics & Gynecology doctors found. Showing 1 - 2

Miss Monika Wyganowska Mansmann, PA-C Obstetrics & Gynecology - Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2325 Heritage Center Dr Ste 605, Furlong, PA 18925 Phone: 215-874-4200    Fax: 215-918-8808

Dr. Victoria Morey Petty, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2325 Heritage Center Dr Ste 605, Furlong, PA 18925 Phone: 215-874-4200    Fax: 215-918-8808

News Archive

Transcendental Meditation technique helps prevent left ventricular hypertrophy

A randomized controlled study recently published in Ethnicity & Disease in their Autumn 2019 Hypertension issue found that the Transcendental Meditation technique helps to prevent abnormal enlargement of the heart compared to health education controls.

State roundup: Md.'s medical home; N.Y. malpractice action; Texas nursing homes

Instead of a doctor seeing patients mostly when they're sick -; and the physician is getting paid for that visit or service -; this program gives financial rewards to practices that use a team of doctors, nurses and other staff to treat the whole person on a continuing basis, not just for one illness. ... The state initiative is among dozens of public and private experiments across the country that are trying to fundamentally change the way doctors practice medicine.

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

KV Pharmaceutical to continue trading on NYSE till March 31, 2010

KV Pharmaceutical Company ( KVa/KVb) (the "Company") received permission from the New York Stock Exchange (the "Exchange") for its securities to continue to trade on the Exchange until March 31, 2010 while the Company prepares its Annual Report on Form 10-K for the Company's fiscal year ended March 31, 2009 (the "2009 Annual Report").

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

Read more Medical News

› Verified 7 days ago